AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Sitglip-M 50/500 Tablet

Prescription Icon
Prescription Required

Marketer

Abrowell Pharmaceuticals

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Sitglip-M 50/500 Tablet

Metformin/Sitagliptin 50/500mg tablets combine two medications to manage elevated blood glucose in type 2 diabetes patients. This dual action helps mitigate serious diabetic complications like vision impairment and kidney disease, potentially lowering the risk of stroke or heart attack. This medication may be used independently or alongside other diabetes treatments and is most effective with a balanced diet and regular physical activity. Dosage is tailored to your specific health status, blood sugar readings, and existing medications. Consuming it with food minimizes stomach upset. Consistent daily use, at the same time each day, maximizes therapeutic benefits; discontinuation requires physician approval. Adherence to your doctor's dietary and exercise plan is crucial for optimal diabetes control, as lifestyle significantly impacts blood sugar management. Common side effects may include nausea, diarrhea, vomiting, stomach discomfort, headache, and throat irritation. Low blood sugar (hypoglycemia) is a potential risk when combined with insulin or sulfonylureas; learn to recognize and address this complication. This medication isn't universally appropriate. Inform your physician of any pre-existing kidney, liver, heart, or pancreatic conditions, or excessive alcohol consumption before commencing treatment. Pregnant or lactating individuals should seek medical consultation prior to use. Interaction with other medications is possible; fully disclose all medications to your doctor to ensure treatment safety. Alcohol should be minimized due to its blood sugar-lowering effect. Your doctor will monitor kidney function and blood glucose levels throughout treatment.

Uses of Sitglip-M 50/500 Tablet

Managing Type 2 diabetes

Major Benefits of Sitglip-M 50/500 Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the Sitglip-M 50/500 Tablet whole; avoid chewing, crushing, or fracturing it. It should be taken with a meal.

Common Side effects of Sitglip-M 50/500 Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Sitglip-M 50/500 Tablet:

Follow your physician's instructions precisely regarding dosage and treatment length for this medication. Ingest the Sitglip-M 50/500 Tablet whole; do not damage it by chewing, crushing, or breaking. Administer this medication with a meal.

How Sitglip-M 50/500 Tablet works:

Sitagliptin and metformin, combined as Sitglip-M 50/500 Tablet, work synergistically to manage blood glucose. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and diminishes hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and increases insulin sensitivity. This dual action leads to improved glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Sitglip-M 50/500 Tablet with alcohol is not advisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Sitglip-M 50/500 Tablet during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible hazards prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Sitglip-M 50/500 tablets while breastfeeding is likely inadvisable. Preliminary human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Sitglip-M 50/500 Tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates Sitglip-M 50/500 Tablet use. Physician consultation is essential. Regular kidney function monitoring is recommended during treatment.

LiverLiverUNSAFE

Patients with liver disease should likely avoid Sitglip-M 50/500 Tablets due to potential safety concerns. Medical advice is recommended.

What if you forget to take Sitglip-M 50/500 Tablet :

Should you forget to take your Sitglip-M 50/500 Tablet, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Sitglip-M 50/500 Tablet

LabelValue
Developing Habits No.
Type of Treatment Diabetes Management

FAQs on Sitglip-M 50/500 Tablet

Sitglip-M 50/500 tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood glucose control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged Sitglip-M 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency, if left untreated, may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Sitglip-M 50/500 Tablet may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Sitglip-M 50/500 Tablet components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Sitglip-M 50/500 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitagliptin/Metformin (Sitglip-M 50/500 Tablet) can cause lactic acidosis (MALA, Metformin-associated lactic acidosis), a serious medical emergency resulting from excessive blood lactic acid. This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Sitglip-M 50/500 tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Sitglip-M 50/500 Tablet may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects include lactic acidosis. Prolonged use may result in vitamin B12 deficiency.
Patients allergic to Sitglip-M 50/500 Tablet components or excipients, or with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Sitglip-M 50/500 tablets with alcohol is unsafe and may raise your risk of lactic acidosis.
Sitagliptin/Metformin (Sitglip-M 50/500) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare side effect necessitates caution in patients with kidney disease, the elderly, and heavy alcohol users. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Prolonged Sitglip-M 50/500 Tablet use can lead to vitamin B12 deficiency by impairing its absorption. This deficiency, if left untreated, may result in anemia, neurological issues such as numbness and tingling in the extremities, weakness, urinary problems, cognitive changes, and balance difficulties (ataxia). To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, as directed on the label or packaging. Dispose of any unused medication properly and keep it out of reach of children, pets, and others.
Sitglip-M 50/500 Tablet combines sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood glucose control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Sitglip-M 50/500 Tablet may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may result in vitamin B12 deficiency.
Sitglip-M 50/500 Tablets are contraindicated in patients with allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitglip-M 50/500 tablets with alcohol is unsafe and may raise your risk of lactic acidosis.
Sitagliptin/Metformin (Sitglip-M 50/500) can cause lactic acidosis (MALA—Metformin-associated lactic acidosis), a serious medical emergency resulting from excess lactic acid in the blood. This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Prolonged Sitglip-M 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the instructions on the label or packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitglip-M 50/500 Tablet
186